BeOne Medicines AG (ONC)
BeOne Medicines AG (ONC) Stock Price, Analysis & Data
| Bid | 185 |
| Market Cap | 40.49B |
| Revenue (ttm) | 6.13B |
| Net Income (ttm) | 655.71M |
| Beta | 0.50 |
| EPS (ttm) | 5.6 |
| PE Ratio (ttm) | 63.92 |
| Forward PE | 34.8 |
| P/B (ttm) | 7.72 |
| P/S (ttm) | 6.61 |
| Earnings Date | Nov 5, 2026 |
| Ask | 358.95 |
| Volume | 215,409 |
| Avg. Volume (20D) | 337,685 |
| Open | 355.61 |
| Previous Close | 359.27 |
| Day's Range | 353.34 - 359.62 |
| 52-Week Range | 253.95 - 385.22 |
| Analyst | Strong Buy |
| Price Target | 427.5 (19.43%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ONC
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVA...
Financial Performance
In 2025, BeOne Medicines's revenue was 5.34B, an increase of 40.23% compared to the previous year's 3.81B. Earnings were 286.93M, a decrease of -144.5%.
Financial StatementsAnalyst Forecast
According to 26 analyst ratings, the average rating for ONC stock is "Strong Buy". The 12-month stock price forecast is 427.5, which is upside of 19.43% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
